FIELD: chemistry.
SUBSTANCE: invention relates to peptides (glucagon and/or GLP-1 and analogues thereof), covalently bound with surface-active glycosides, intended for treating or preventing disorders associated with insulin resistance.
EFFECT: modification of peptides promotes longer action and/or increased bioavailability of peptides.
17 cl, 1 tbl, 3 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
| PHARMACEUTICAL COMPOSITIONS OF hGLP-1, EXENDIN-4 AND THEIR ANALOGUES | 2007 |
|
RU2419452C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
